Literature DB >> 9721858

Identification of nonproliferating but viable hypoxic tumor cells in vivo.

R E Durand1, J A Raleigh.   

Abstract

We have used the combination of pimonidazole labeling of hypoxic cells, bromodeoxyuridine labeling of proliferating cells, and cell sorting based on Hoechst 33342 perfusion to directly study hypoxia and proliferation in human tumor xenografts and transplantable murine tumors in vivo. Hypoxia was largely confined to cells in regions with the least perfusion, although in tumors exhibiting transient blood flow, hypoxic cells were not as highly localized. Similarly, proliferation and hypoxia were mutually exclusive except in areas of a tumor subjected to transient changes in perfusion. By determining the clonogenic potential, pimonidazole labeling intensity, and radiosensitivity of sorted tumor cell subpopulations, we have provided direct evidence that pimonidazole identifies hypoxic tumor cells of therapeutic relevance in vivo. Given that pimonidazole exhibits few diffusion or delivery problems and no apparent cytotoxicity, it appears to be a versatile and useful label for hypoxic cells in solid tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721858

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Early wound healing exhibits cytokine surge without evidence of hypoxia.

Authors:  Z A Haroon; J A Raleigh; C S Greenberg; M W Dewhirst
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  From anatomical to biological target volumes: the role of PET in radiation treatment planning.

Authors:  D A X Schinagl; J H A M Kaanders; W J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

3.  Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas.

Authors:  H W M van Laarhoven; G Gambarota; A Heerschap; J Lok; I Verhagen; A Corti; S Toma; C Gallo Stampino; A van der Kogel; C J A Punt
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

4.  The hypoxic tumor microenvironment in vivo selects tumor cells with increased survival against genotoxic stresses.

Authors:  Hoon Kim; Qun Lin; Zhong Yun
Journal:  Cancer Lett       Date:  2018-05-30       Impact factor: 8.679

Review 5.  Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity.

Authors:  Chao Liu; Qun Lin; Zhong Yun
Journal:  Radiat Res       Date:  2015-05-04       Impact factor: 2.841

6.  Hypoxia in renal disease with proteinuria and/or glomerular hypertension.

Authors:  Tetsuhiro Tanaka; Toshio Miyata; Reiko Inagi; Toshiro Fujita; Masaomi Nangaku
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 7.  Hypoxia in microscopic tumors.

Authors:  Xiao-Feng Li; Joseph A O'Donoghue
Journal:  Cancer Lett       Date:  2008-04-01       Impact factor: 8.679

8.  Combined Injection of (18)F-Fluorodeoxyglucose and 3'-Deoxy-3'-[(18)F]fluorothymidine PET Achieves More Complete Identification of Viable Lung Cancer Cells in Mice and Patients than Individual Radiopharmaceutical: A Proof-of-Concept Study.

Authors:  Xiao-Feng Li; Tao Huang; Huijie Jiang; Xuemei Wang; Baozhong Shen; Xiangcheng Wang; Chin K Ng; Gregory C Postel; A Cahid Civelek
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

9.  Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates.

Authors:  Laura E Via; P Ling Lin; Sonja M Ray; Jose Carrillo; Shannon Sedberry Allen; Seok Yong Eum; Kimberly Taylor; Edwin Klein; Ujjini Manjunatha; Jacqueline Gonzales; Eun Gae Lee; Seung Kyu Park; James A Raleigh; Sang Nae Cho; David N McMurray; JoAnne L Flynn; Clifton E Barry
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

10.  Pimonidazole binding in C6 rat brain glioma: relation with lipid droplet detection.

Authors:  S Zoula; P F J W Rijken; J P W Peters; R Farion; B P J Van der Sanden; A J Van der Kogel; M Décorps; C Rémy
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.